Urokinase in the treatment of intraventricular hemorrhage.
Large, randomized, double-blind trials on the use of urokinase for IVH are not available, and the studies published in the literature are not without flaws. However, it appears that in the current case-control reports, administration of urokinase through ventricular catheters is safe and is a promising alternative to current medical or surgical management. Investigation of other fibrinolytic agents such as recombinant alteplase is available, but is even more limited. Further trials will help to determine the best dosage and duration of urokinase therapy, as well as the overall efficacy of this new treatment option.
Murry
K R
KR
Department of Pharmacy Services, Detroit Receiving Hospital, MI, USA. kmurry@dmc.org
Rhoney
D H
DH
Coplin
W M
WM
D002986:Clinical Trials as Topic; D006331:Heart Diseases / Q000188:drug therapy*; D006352:Heart Ventricles; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator